Nadirah Rasyid Ridha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadirah Rasyid Ridha has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Ema Alasiry
Department of Pediatrics, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
3 shared publicationsBahrul Fikri
Department of Pediatrics, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 shared publicationsKwari Januar Satriono
Department of Pediatric, Faculty of Medicine, Hasanuddin University
2 shared publicationsAmiruddin L
Department of Pediatric, Faculty of Medicine, Hasanuddin University
1 shared publicationAndi Alfian Zainuddin
Department of Public Health and Community Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
1 shared publicationAndi Ayu Hafsari
Universitas Hasanuddin Makassar
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (9) , 3265-3270
Serum Vitamin D Levels and Vitamin D Receptor Concentrations in Children with Acute Lymphoblastic Leukemia: A Cross-Sectional Study
Introduction: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, characterized by the proliferation of immature lymphoid cells. Vitamin D and its receptor (VDR) play a critical role in immune regulation and cancer progression. This study investigated serum vitamin D levels and VDR concentrations in children with ALL and their relationship with clinical risk groups. Methods: This cross-sectional study involved 90 children categorized into standard risk (SR), high risk (HR), and control groups at Dr. Wahidin Sudirohusodo Hospital in Makassar, Indonesia. Serum vitamin D levels and soluble VDR concentrations were measured using ELISA. Vitamin D status was classified as deficient (30ng/mL). Statistical analysis compared the groups and examined associations with SPPS version 26. Results: Vitamin D deficiency was prevalent in 82.2% of ALL patients. The SR and HR groups showed significantly lower levels than controls (P<0.001). Median vitamin D levels were 13.29ng/mL (SR), 13.94ng/mL (HR), and 19.61 ng/mL (control). Median VDR concentrations were highest in the SR group (0.600ng/mL), though differences across groups were not statistically significant (P=0.163). A positive correlation between serum vitamin D levels and VDR concentrations was identified (P=0.001, r=0.342). Conclusion: Vitamin D deficiency is highly prevalent in children with ALL, highlighting the need for regular vitamin D screening and supplementation. Further research is necessary to explore the therapeutic potential of vitamin D and VDR in leukemia treatment.
- 1 September 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (9) , 3265-3270
Open AccessSerum Vitamin D Levels and Vitamin D Receptor Concentrations in Children with Acute Lymphoblastic Leukemia: A Cross-Sectional Study
Introduction: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, characterized by the proliferation of immature lymphoid cells. Vitamin D and its receptor (VDR) play a critical role in immune regulation and cancer progression. This study investigated serum vitamin D levels and VDR concentrations in children with ALL and their relationship with clinical risk groups. Methods: This cross-sectional study involved 90 children categorized into standard risk (SR), high risk (HR), and control groups at Dr. Wahidin Sudirohusodo Hospital in Makassar, Indonesia. Serum vitamin D levels and soluble VDR concentrations were measured using ELISA. Vitamin D status was classified as deficient (30ng/mL). Statistical analysis compared the groups and examined associations with SPPS version 26. Results: Vitamin D deficiency was prevalent in 82.2% of ALL patients. The SR and HR groups showed significantly lower levels than controls (P<0.001). Median vitamin D levels were 13.29ng/mL (SR), 13.94ng/mL (HR), and 19.61 ng/mL (control). Median VDR concentrations were highest in the SR group (0.600ng/mL), though differences across groups were not statistically significant (P=0.163). A positive correlation between serum vitamin D levels and VDR concentrations was identified (P=0.001, r=0.342). Conclusion: Vitamin D deficiency is highly prevalent in children with ALL, highlighting the need for regular vitamin D screening and supplementation. Further research is necessary to explore the therapeutic potential of vitamin D and VDR in leukemia treatment.
- Open Access
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (3.4) , 337-342
Effectiveness of Combined Vitamin D and Iron Supplementation on Iron Status in Children with Iron Deficiency Anemia: A Randomized Controlled Trial
Introduction:Vitamin D may reduce inflammation by affecting cytokine production, potentially alleviating chronic anemia. Iron deficiency can impair vitamin D absorption, yet the interaction between these deficiencies remains unclear. This study aimed to evaluate the effectiveness of combined vitamin D and iron supplementation in treating iron deficiency anemia (IDA) in children. Methods:An open-label, randomized controlled trial was conducted at four outpatient clinics and Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia. Of 250 assessed patients, 67 met the inclusion criteria. Participants were randomized into two groups:Group A received iron supplementation (3 mg/kg BW/day), while Group B received iron combined with vitamin D (400 IU). Treatment lasted 4 weeks, and iron status was evaluated pre- and post-treatment. Results:No significant changes were observed in complete blood count, serum iron, and ferritin levels after 4 weeks in either group (p>0.05). However, the mean change in serum ferritin levels was significantly greater in the combined group (p=0.039). Conclusion:Both iron alone and iron with vitamin D improved hematological parameters in children with iron deficiency anemia. Combined iron and vitamin D therapy showed a significant ferritin increase, suggesting that adding vitamin D may support better iron storage. J. Med. Invest. 72 : 337-342, August, 2025
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (3.4) , 337-342
Open AccessEffectiveness of Combined Vitamin D and Iron Supplementation on Iron Status in Children with Iron Deficiency Anemia: A Randomized Controlled Trial
Introduction:Vitamin D may reduce inflammation by affecting cytokine production, potentially alleviating chronic anemia. Iron deficiency can impair vitamin D absorption, yet the interaction between these deficiencies remains unclear. This study aimed to evaluate the effectiveness of combined vitamin D and iron supplementation in treating iron deficiency anemia (IDA) in children. Methods:An open-label, randomized controlled trial was conducted at four outpatient clinics and Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia. Of 250 assessed patients, 67 met the inclusion criteria. Participants were randomized into two groups:Group A received iron supplementation (3 mg/kg BW/day), while Group B received iron combined with vitamin D (400 IU). Treatment lasted 4 weeks, and iron status was evaluated pre- and post-treatment. Results:No significant changes were observed in complete blood count, serum iron, and ferritin levels after 4 weeks in either group (p>0.05). However, the mean change in serum ferritin levels was significantly greater in the combined group (p=0.039). Conclusion:Both iron alone and iron with vitamin D improved hematological parameters in children with iron deficiency anemia. Combined iron and vitamin D therapy showed a significant ferritin increase, suggesting that adding vitamin D may support better iron storage. J. Med. Invest. 72 : 337-342, August, 2025
- Open Access
- 30 January 2024
- Published by Universitas Islam Negeri Alauddin Makassar in Alami Journal (Alauddin Islamic Medical) Journal
- Vol. 8 (1) , 56-62
Successful Multidrug Chemotherapy for Rhabdomyosarcoma in a Seven-Year-Old Girl: A Case Report
The most frequent soft tissue cancer in children is rhabdomyosarcoma (RMS). A diagnosis typically occurs between the ages of 5 and 6 in women. We report a seven-year-old girl was referred to Hospitals with complaints of a protruding left eye. The swelling was presented in July 2021, which was small earlier but has increased and become more prominent. An examination of the left eyelid showed a 2.5 x 2.5 x 1.5 cm solid mass with edema, erythema, and secretion in the superior and inferior affected eyelid. A Head CT scan revealed a left superolateral lacrimal duct tumour with a normal intracerebral structure. The histopathology examination found dacryoadenitis with an RMS tumour. This patient was treated using the RMS multidrug chemotherapy protocol (vincristine, actinomycin, and cyclophosphamide) for three sessions, which decreased tumour progressivity five months later. Early and appropriate treatment of this patient with chemotherapy regimens according to the protocol for RMS has a good prognosis.
- 30 January 2024
- Published by Universitas Islam Negeri Alauddin Makassar in Alami Journal (Alauddin Islamic Medical) Journal
- Vol. 8 (1) , 56-62
Open AccessSuccessful Multidrug Chemotherapy for Rhabdomyosarcoma in a Seven-Year-Old Girl: A Case Report
The most frequent soft tissue cancer in children is rhabdomyosarcoma (RMS). A diagnosis typically occurs between the ages of 5 and 6 in women. We report a seven-year-old girl was referred to Hospitals with complaints of a protruding left eye. The swelling was presented in July 2021, which was small earlier but has increased and become more prominent. An examination of the left eyelid showed a 2.5 x 2.5 x 1.5 cm solid mass with edema, erythema, and secretion in the superior and inferior affected eyelid. A Head CT scan revealed a left superolateral lacrimal duct tumour with a normal intracerebral structure. The histopathology examination found dacryoadenitis with an RMS tumour. This patient was treated using the RMS multidrug chemotherapy protocol (vincristine, actinomycin, and cyclophosphamide) for three sessions, which decreased tumour progressivity five months later. Early and appropriate treatment of this patient with chemotherapy regimens according to the protocol for RMS has a good prognosis.
- Open Access
- 20 March 2023
- Published by Universitas Negeri Gorontalo in International Journal of Health Science & Medical Research
- Vol. 2 (2) , 76-84
ANALYSIS OF MALONDIALDEHYDE LEVELS IN CHILDREN WITH BETA THALASSEMIA: A CROSS-SECTIONAL STUDY
Beta thalassemia is an autosomal recessive genetic condition affecting people worldwide, including in Indonesia. Malondialdehyde levels, a peroxidation product, can be used to see if there is an iron buildup in the body due to lifelong transfusions. This research is a novelty because it analyzes malondialdehyde levels in children with beta-thalassemia: a cross-section study. The study aims to analyze malondialdehyde levels in children with beta-thalassemia. Methods in this study, a cross-sectional investigation was carried out at Dr. Hospital Wahidin Sudirohusodo, Makassar. The study was carried out between April and August of 2022. The study sample consisted of participants diagnosed with beta-thalassemia and non-thalassemia (controls) eligible to participate. Patients with and without beta-thalassemia had their malondialdehyde levels measured. The study results showed that the 60 children, aged six months until 18 years, were separated into two groups, 30 of whom had beta-thalassemia and another 30 who did not. With a significant P-value of 0.000, it was determined that beta-thalassemia children had more substantial amounts of malondialdehyde than children without the condition. Children with beta-thalassemia major had significantly higher malondialdehyde levels than those with beta-thalassemia HbE (P-value = 0.000). The conclusion was that malondialdehyde levels were more significant in beta-thalassemia kids than non-thalassemia kids. Malondialdehyde values are more effective in kids with beta-thalassemia major than those with beta-HbE thalassemia. Keywords: Malondialdehyde; Beta thalassemia; Transfusion; Children.
- 20 March 2023
- Published by Universitas Negeri Gorontalo in International Journal of Health Science & Medical Research
- Vol. 2 (2) , 76-84
Open AccessANALYSIS OF MALONDIALDEHYDE LEVELS IN CHILDREN WITH BETA THALASSEMIA: A CROSS-SECTIONAL STUDY
Beta thalassemia is an autosomal recessive genetic condition affecting people worldwide, including in Indonesia. Malondialdehyde levels, a peroxidation product, can be used to see if there is an iron buildup in the body due to lifelong transfusions. This research is a novelty because it analyzes malondialdehyde levels in children with beta-thalassemia: a cross-section study. The study aims to analyze malondialdehyde levels in children with beta-thalassemia. Methods in this study, a cross-sectional investigation was carried out at Dr. Hospital Wahidin Sudirohusodo, Makassar. The study was carried out between April and August of 2022. The study sample consisted of participants diagnosed with beta-thalassemia and non-thalassemia (controls) eligible to participate. Patients with and without beta-thalassemia had their malondialdehyde levels measured. The study results showed that the 60 children, aged six months until 18 years, were separated into two groups, 30 of whom had beta-thalassemia and another 30 who did not. With a significant P-value of 0.000, it was determined that beta-thalassemia children had more substantial amounts of malondialdehyde than children without the condition. Children with beta-thalassemia major had significantly higher malondialdehyde levels than those with beta-thalassemia HbE (P-value = 0.000). The conclusion was that malondialdehyde levels were more significant in beta-thalassemia kids than non-thalassemia kids. Malondialdehyde values are more effective in kids with beta-thalassemia major than those with beta-HbE thalassemia. Keywords: Malondialdehyde; Beta thalassemia; Transfusion; Children.
- Open Access
- 20 March 2023
- Published by Universitas Negeri Gorontalo in International Journal of Health Science & Medical Research
- Vol. 2 (2) , 66-75
COMPARISON OF TRANSFERRIN SATURATION LEVELS IN ANEMIA OF CHRONIC DISEASE AND IRON DEFICIENCY ANEMIA: A CROSS-SECTIONAL STUDY
About 33 percent of the global population is anemic. Anemia of chronic disease (ACD) is caused by chronic inflammation. Iron deficiency anemia (IDA) is caused by a decrease in the body's iron reserves to form red blood cells. There are many clinical and laboratory similarities between ACD and IDA, but the treatment is very different. Transferrin saturation level can be used to differentiate between the two. This research is novel because it compares transferrin saturation levels in chronic and iron deficiency anemia. This study aims to determine the transferrin saturation level in patients with ACD and IDA. This research method uses a cross-sectional study. Data taken from medical records. The sample for this study were children with ACD and IDA aged 1 month to 18 years at Wahidin Sudirohusodo Hospital, Makassar. The results showed that the mean transferrin saturation value in DKA children (19.40%) was higher than that in ADB children (5.66%). The Mann-Whitney test showed that there was a significant difference between the two groups (p=0.001) with a transferrin saturation cut-off point between the DKA and IDA groups of 6.5% with a sensitivity of 73.6%, a specificity of 72.5%, positive predictive value (PPV) of 78%, negative predictive value (NPV) of 67%, and odds ratio (OR) of 19,476 (95% CI). In conclusion, transferrin saturation levels can differentiate IDA and ACD using a cut-off point of 6.5%.
- 20 March 2023
- Published by Universitas Negeri Gorontalo in International Journal of Health Science & Medical Research
- Vol. 2 (2) , 66-75
Open AccessCOMPARISON OF TRANSFERRIN SATURATION LEVELS IN ANEMIA OF CHRONIC DISEASE AND IRON DEFICIENCY ANEMIA: A CROSS-SECTIONAL STUDY
About 33 percent of the global population is anemic. Anemia of chronic disease (ACD) is caused by chronic inflammation. Iron deficiency anemia (IDA) is caused by a decrease in the body's iron reserves to form red blood cells. There are many clinical and laboratory similarities between ACD and IDA, but the treatment is very different. Transferrin saturation level can be used to differentiate between the two. This research is novel because it compares transferrin saturation levels in chronic and iron deficiency anemia. This study aims to determine the transferrin saturation level in patients with ACD and IDA. This research method uses a cross-sectional study. Data taken from medical records. The sample for this study were children with ACD and IDA aged 1 month to 18 years at Wahidin Sudirohusodo Hospital, Makassar. The results showed that the mean transferrin saturation value in DKA children (19.40%) was higher than that in ADB children (5.66%). The Mann-Whitney test showed that there was a significant difference between the two groups (p=0.001) with a transferrin saturation cut-off point between the DKA and IDA groups of 6.5% with a sensitivity of 73.6%, a specificity of 72.5%, positive predictive value (PPV) of 78%, negative predictive value (NPV) of 67%, and odds ratio (OR) of 19,476 (95% CI). In conclusion, transferrin saturation levels can differentiate IDA and ACD using a cut-off point of 6.5%.
- Open Access
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (B) , 2586-2590
Evaluation of Interleukin-6 Level Before Chemotherapy in Acute Lymphoblastic Leukemia L1 Standard-Risk and High-risk Patients
BACKGROUND: Acute lymphoblastic leukemia (ALL) is a malignancy originating from the clonal expansion of lymphoid progenitors that have undergone neoplastic transformation at various stages of differentiation. Interleukin-6 (IL-6) is a pleiotropic inflammatory cytokine produced by various cell types, including T-cells, macrophages, and stromal cells in response to tumor necrosis factor-alpha and interleukin-1. AIM: This study aims to evaluate serum levels of IL-6 before chemotherapy in standard-risk (SR) and high-risk (HR) ALL patients. METHODS: The research method was a cross-sectional study conducted on ALL patients who were treated at Dr. Wahidin Sudirohusodo hospital from April 2021 to June 2021. A total of 60 ALL patients were included in the study. Serum IL-6 specimens were examined before the patient received chemotherapy. RESULTS: The results showed that from 60 samples of ALL patients, 30 were SR and 30 were HR. Elevated levels of IL-6 before chemotherapy were found in both SR and HR ALL but were significantly higher in the HR group compared to the SR group with p value = 0.022. The cutoff point of 64.23 ng/mL for HRALL patients was obtained through ROC with a sensitivity of 63.3%, specificity of 63.3%, a positive predictive value of 63.3%, and a negative predictive value of 63.3%. Adjusted odds ratio are 2,983 with 95% confidence interval of 1.044–8.527. CONCLUSION: IL-6 levels among HR ALL were higher than SR. Elevated levels of IL-6 were found in both SR and HR ALL.
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (B) , 2586-2590
Open AccessEvaluation of Interleukin-6 Level Before Chemotherapy in Acute Lymphoblastic Leukemia L1 Standard-Risk and High-risk Patients
BACKGROUND: Acute lymphoblastic leukemia (ALL) is a malignancy originating from the clonal expansion of lymphoid progenitors that have undergone neoplastic transformation at various stages of differentiation. Interleukin-6 (IL-6) is a pleiotropic inflammatory cytokine produced by various cell types, including T-cells, macrophages, and stromal cells in response to tumor necrosis factor-alpha and interleukin-1. AIM: This study aims to evaluate serum levels of IL-6 before chemotherapy in standard-risk (SR) and high-risk (HR) ALL patients. METHODS: The research method was a cross-sectional study conducted on ALL patients who were treated at Dr. Wahidin Sudirohusodo hospital from April 2021 to June 2021. A total of 60 ALL patients were included in the study. Serum IL-6 specimens were examined before the patient received chemotherapy. RESULTS: The results showed that from 60 samples of ALL patients, 30 were SR and 30 were HR. Elevated levels of IL-6 before chemotherapy were found in both SR and HR ALL but were significantly higher in the HR group compared to the SR group with p value = 0.022. The cutoff point of 64.23 ng/mL for HRALL patients was obtained through ROC with a sensitivity of 63.3%, specificity of 63.3%, a positive predictive value of 63.3%, and a negative predictive value of 63.3%. Adjusted odds ratio are 2,983 with 95% confidence interval of 1.044–8.527. CONCLUSION: IL-6 levels among HR ALL were higher than SR. Elevated levels of IL-6 were found in both SR and HR ALL.
- Open Access
- 16 April 2015
- Published by Science Publishing Group in American Journal of Clinical and Experimental Medicine
- Vol. 3 (3) , 124-127
Age as a Risk Factor of Relapse Occurrence in Acute Lymphoblastic Leukemia-L1 (All-L1) in Children
Introduction: Relapse in children with leukemia is a phase appearing the leukemia cells after complete remission; this situation can impact the children itself, parents and also the support system. Objective: To identify the factors related of relapse incidence in children with leukemia. Methods: This study was conducted by using a retrospective cohort study design based on medical record data from Dr. Wahidin Sudirohusodo Hospital, Makassar from December 2013 until August 2014. Study samples were children of 0 month – 18 years old diagnosed of having Acute Lymphoblastic Leukemia-L1. They are treated with chemotherapy and divided into relapse and non-relapse samples. Results: From 42 relapse and non-relapse samples, there were 35.7% (15) relapse samples and 64.3% (27) non relapse samples. Bivariate analyses revealed that among 1-10 year, there were 31.4% (11) with relapse and 68.6% (24) without relapse. Among the samples aged more than 10 years old, there were 57.1% (4) samples with relapse and 42.9% (3) samples without relapse, with p=0.225 (p>0.05). In terms of interval time from first diagnosis until the occurrence of relapse, the median value was 1.80 in 1-10 year-old group. In the group of >10 years old, the median value was 0.84 and p=0.207 (p>0.05). Conclusion: Age did not give any influence in the incidence of relapse in children with ALL-L1 and the interval time when the first diagnosed until relapse.
- 16 April 2015
- Published by Science Publishing Group in American Journal of Clinical and Experimental Medicine
- Vol. 3 (3) , 124-127
Open AccessAge as a Risk Factor of Relapse Occurrence in Acute Lymphoblastic Leukemia-L1 (All-L1) in Children
Introduction: Relapse in children with leukemia is a phase appearing the leukemia cells after complete remission; this situation can impact the children itself, parents and also the support system. Objective: To identify the factors related of relapse incidence in children with leukemia. Methods: This study was conducted by using a retrospective cohort study design based on medical record data from Dr. Wahidin Sudirohusodo Hospital, Makassar from December 2013 until August 2014. Study samples were children of 0 month – 18 years old diagnosed of having Acute Lymphoblastic Leukemia-L1. They are treated with chemotherapy and divided into relapse and non-relapse samples. Results: From 42 relapse and non-relapse samples, there were 35.7% (15) relapse samples and 64.3% (27) non relapse samples. Bivariate analyses revealed that among 1-10 year, there were 31.4% (11) with relapse and 68.6% (24) without relapse. Among the samples aged more than 10 years old, there were 57.1% (4) samples with relapse and 42.9% (3) samples without relapse, with p=0.225 (p>0.05). In terms of interval time from first diagnosis until the occurrence of relapse, the median value was 1.80 in 1-10 year-old group. In the group of >10 years old, the median value was 0.84 and p=0.207 (p>0.05). Conclusion: Age did not give any influence in the incidence of relapse in children with ALL-L1 and the interval time when the first diagnosed until relapse.